Tumor Lysis Syndrome
Urate Oxidase
Gout Suppressants
Allopurinol
Hyperuricemia
Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
Leukemia, Lymphocytic, Chronic, B-Cell
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
Hematologic Neoplasms
Allopurinol: intravenous use for prevention and treatment of hyperuricemia. (1/55)
PURPOSE: To tabulate data obtained over a 21-year period to determine the efficacy and safety of an intravenous (IV) allopurinol preparation. PATIENTS AND METHODS: IV allopurinol was provided on a compassionate plea basis to patients of any age in whom xanthine oxidase inhibitor therapy was indicated as an adjunct to chemotherapy and for whom oral intake was restricted. Three hundred twenty-seven investigators at multiple hospitals in the United States treated 1,172 patients with IV allopurinol. The vast majority of these patients had a malignancy and were in danger of developing tumor lysis syndrome (TLS) and subsequent acute uric acid nephropathy (AUAN) and were unable to take oral allopurinol. Data referable to the time period of IV allopurinol administration were collected, collated, and analyzed retrospectively. There was no randomization. RESULTS: In patients initiating treatment for an elevated serum uric acid (SUA), the SUA normalized or improved in 87% of adult patients and normalized or improved in 95% of pediatric patients. IV allopurinol, administered prophylactically to patients at high risk of developing hyperuricemia and TLS, prevented an increase in SUA levels in 93% of adults and 92% of children. Toxicities caused by IV allopurinol were minimal and consisted of 10 instances of mild to moderate skin or allergic reactions. CONCLUSION: IV allopurinol is as efficacious and safe as oral allopurinol and will be of significant benefit to patients at risk of TLS and AUAN and unable to take oral medication. (+info)Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review. (2/55)
A patient with a small-cell lung cancer (SCLC) developed an asymptomatic hyponatremia, with all features of the syndrome of inappropriate antidiuretic hormone secretion (SIADH), two days after the start of his first cycle of chemotherapy with vindesine, ifosfamide and cisplatin. Progression of the tumour with an increase in paraneoplastic SIADH, or drug-induced causes of hyponatremia, could be ruled out by his further clinical course. The event was interpreted as a consequence of ADH release during the initial tumour cell lysis after effective chemotherapy. The occurrence of hyponatremia during the initial phase of chemotherapy for SCLC should be interpreted with caution. Although it is most commonly due to an increase in paraneoplastic ADH secretion reflecting ineffective therapy, it can also be due to release of ADH from malignant cells in the period of rapid tumour lysis, reflecting effective therapy. Based on this rare occurrence, a review of the aetiology, clinical findings, diagnosis, prognosis and treatment of SIADH in general is presented. (+info)Tumor lysis syndrome following hemi-body irradiation for metastatic breast cancer. (3/55)
Tumor lysis syndrome (TLS) is a rare serious acute complication of cancer therapy, reported mainly following chemotherapy in patients with large tumor load and chemosensitive disease. These are mainly patients with non-Hodgkin's lymphoma, leukemia and rarely in solid tumors. It is less frequently described after radiotherapy for lymphoid and hematological malignancies. TLS following radiotherapy for solid tumors is a very rare complication. In this report/review we describe a seventy-three-year-old male patient with progressive metastatic carcinoma of the breast to the lungs, liver and bone. He was referred for radiotherapy because of generalized bony pains. The patient was planned for sequential hemi-body irradiation starting with the more symptomatic upper half body. After premedication, he was given 8.5 Gy to the mid point at the maximum chest separation with anterior lung attenuator limiting uncorrected lung dose to 6.15 Gy. A further 3.5 Gy electron boost to the fungating breast tumor was given to the 100%. Forty-eight hours after irradiation he developed hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia and renal failure. These clinical and biochemical changes are typical of tumor lysis syndrome (TLS). Despite hydration, and treating the hyperuricemia, the patient developed coma and died eight days after irradiation. The prophylaxis and management of TLS and in high-risk patients are described to avoid this frequently fatal complication. (+info)Spontaneous acute tumor lysis syndrome with advanced gastric cancer. (4/55)
Acute tumor lysis syndrome (TLS) occurs frequently in hematologic malignancies such as high-grade lymphomas and acute leukemia, which are rapidly proliferating and chemosensitive tumors. It occurs rarely in solid tumors and has never been reported in gastric adenocarcinoma. Typical biochemical findings of acute tumor lysis syndrome are hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia in patients with a malignancy. Rapid changes of these electrolytes may cause cardiac arrhythmia, seizure, acute renal failure and sudden death. Therefore, as soon as it is detected, it should be taken care of immediately. Until now almost all cases of TLS associated with solid tumor have developed after cytoreductive therapy in chemosensitive tumors. We report here a case of spontaneous acute tumor lysis in a patient of advanced gastric cancer with hepatic metastases and multiple lymphadenopathy. The biochemical finding of TLS improved with the management and tumor burden also showed slight response to the one cycled combination chemotherapy but the patient died of progressive pneumonia. (+info)A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. (5/55)
Standard therapy in the United States for malignancy-associated hyperuricemia consists of hydration, alkalinization, and allopurinol. Urate oxidase catalyzes the enzymatic oxidation of uric acid to a 5 times increased urine soluble product, allantoin. Rasburicase is a new recombinant form of urate oxidase available for clinical evaluation. This multicenter randomized trial compared allopurinol to rasburicase in pediatric patients with leukemia or lymphoma at high risk for tumor lysis. Patients received the assigned uric acid-lowering agent for 5 to 7 days during induction chemotherapy. The primary efficacy end point was to compare the area under the serial plasma uric acid concentration curves during the first 96 hours of therapy (AUC(0-96)). Fifty-two patients were randomized at 6 sites. In an intent-to-treat analysis, the mean uric acid AUC(0-96) was 128 +/- 70 mg/dL.hour for the rasburicase group and 329 +/- 129 mg/dL.hour for the allopurinol group (P <.0001). The rasburicase versus allopurinol group experienced a 2.6-fold (95% CI: 2.0-3.4) less exposure to uric acid. Four hours after the first dose, patients randomized to rasburicase compared to allopurinol achieved an 86% versus 12% reduction (P <.0001) of initial plasma uric acid levels. No antirasburicase antibodies were detected at day 14. This randomized study demonstrated more rapid control and lower levels of plasma uric acid in patients at high risk for tumor lysis who received rasburicase compared to allopurinol. For pediatric patients with advanced stage lymphoma or high tumor burden leukemia, rasburicase is a safe and effective alternative to allopurinol during initial chemotherapy. (+info)Oncologic emergencies for the internist. (6/55)
Most cancer patients experience at least one emergency during the course of the disease. This paper reviews the diagnosis and treatment of tumor lysis syndrome, hypercalcemia of malignancy, superior vena cava syndrome, spinal cord compression, strokes and seizures, and treatment-related emergencies. (+info)Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. (7/55)
PURPOSE: To evaluate the frequency of metabolic complications and dialysis due to tumor lysis syndrome in patients with B-cell advanced-stage non-Hodgkin's lymphoma (NHL) and L3 leukemia at initiation of chemotherapy including the use of urate-oxidase. PATIENTS AND METHODS: Retrospective review of the clinical records of 410 patients with stage III and IV B-cell NHL and L3 leukemia treated in France and prospectively registered in the LMB89 protocol. RESULTS: During the first week of chemotherapy, only 34 of 410 patients recorded metabolic problems that included hypocalcemia (< 70 mg/dl) in 24 patients, hyperphosphatemia (> 6.5 mg/dl) in 28 and elevation of creatinine > or = 2 SD in 16. Six patients underwent dialysis for life-threatening problems and a seventh as a preventive measure. In the other 27 cases, metabolic problems were successfully resolved using urate-oxidase in combination with alkaline hyperhydration. Among the 410 patients, one case of hemolysis was reported and there was no severe allergic reaction to urate-oxidase. CONCLUSIONS: Only 1.7% of patients in our study receiving urate-oxidase during their induction chemotherapy needed renal dialysis. Urate-oxidase was well tolerated, and used as prophylaxis and/or treatment of hyperuricemia and tumor lysis syndrome consistently gave a lower rate of renal and metabolic complications than in other series of similar patients. (+info)Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. (8/55)
BACKGROUND: Hyperuricemia and tumor lysis syndrome (TLS) are serious complications that can occur during chemotherapy for hematologic malignancies, even if standard management procedures, including administration of allopurinol, are undertaken. Rasburicase, a recombinant urate oxidase that converts uric acid (UA) into the soluble compound allantoin, has been shown to control hyperuricemia faster and more reliably than allopurinol.(1) METHODS: A compassionate use trial, running from January 1999 to December 2001, provided access to rasburicase for patients in nine countries who were at risk for TLS during the initiation of chemotherapy. Of the 280 patients enrolled in the study, 278 received rasburicase and were included in the analysis. A total of 166 pediatric patients who had leukemia (approximately 74%), lymphoma (approximately 24%), or solid tumors (approximately 3%) were treated with rasburicase. One hundred twelve adults with either leukemia (68%) or lymphoma (30%) also were treated. Rasburicase (0.20 mg/kg) was administered intravenously once a day for 1 to 7 days, at the investigator's discretion. Two doses daily could be administered during the first 3 days. A response was defined as a reduction in UA level or maintenance of a UA level less than 7.5 mg/dL (or less than 6.5 mg/dL, for children age < 13 years). RESULTS: UA levels at 24-48 hours after administration of the last dose of rasburicase were available for 122 pediatric patients and 97 adult patients. The mean UA level in 29 hyperuricemic children decreased from 15.1 mg/dL to 0.4 mg/dL, whereas in 27 hyperuricemic adults, the mean level decreased from 14.2 mg/dL to 0.5 mg/dL. Prophylactic administration of rasburicase to prevent TLS during chemotherapy reduced UA levels from a mean of 4.4 mg/dL to 0.8 mg/dL in 93 nonhyperuricemic children and from 4.8 mg/dL to 0.4 mg/dL in 70 nonhyperuricemic adults (for all reductions in UA levels, P < 0.001). The response rate was 100%. Rasburicase was very well tolerated. Serious adverse events related to rasburicase were observed in one patient. CONCLUSIONS: The results of the current study confirm that rasburicase is safe and highly effective in the prevention and treatment of chemotherapy-induced hyperuricemia in both children and adults. (+info)Tumor Lysis Syndrome is a metabolic disturbance characterized by hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia, which may lead to acute renal failure, resulting from the rapid lysis of malignant cells often after the initiation of chemotherapy.
Tumor Lysis Syndrome (TLS) is a metabolic complication that can occur following the rapid destruction of malignant cells, most commonly seen in hematologic malignancies such as acute leukemias and high-grade non-Hodgkin lymphomas. The rapid breakdown of these cancer cells releases a large amount of intracellular contents, including potassium, phosphorus, and nucleic acids, into the bloodstream.
This sudden influx of substances can lead to three major metabolic abnormalities: hyperkalemia (elevated potassium levels), hyperphosphatemia (elevated phosphate levels), and hypocalcemia (low calcium levels). Hyperuricemia (elevated uric acid levels) may also occur due to the breakdown of nucleic acids. These metabolic disturbances can cause various clinical manifestations, such as cardiac arrhythmias, seizures, renal failure, and even death if not promptly recognized and treated.
TLS is classified into two types: laboratory TLS (LTLS) and clinical TLS (CTLS). LTLS is defined by the presence of abnormal laboratory values without any related clinical symptoms, while CTLS is characterized by laboratory abnormalities accompanied by clinical signs or symptoms. Preventive measures, such as aggressive hydration, urinary alkalinization, and prophylactic medications to lower uric acid levels, are often employed in high-risk patients to prevent the development of TLS.
Urate oxidase, also known as uricase, is an enzyme that catalyzes the oxidation of uric acid into allantoin, carbon dioxide, and hydrogen peroxide, playing a crucial role in purine metabolism and typically found in various non-primate mammals, birds, reptiles, and some fish, but not in humans and other primates.
Urate oxidase, also known as uricase, is an enzyme that catalyzes the oxidation of uric acid to allantoin. This reaction is an essential part of purine metabolism in many organisms, as allantoin is more soluble and easier to excrete than uric acid. In humans, urate oxidase is non-functional due to mutations in the gene encoding it, which leads to the accumulation of uric acid and predisposes to gout and kidney stones. Urate oxidase is found in some bacteria, fungi, and plants, and can be used as a therapeutic agent in humans to lower serum uric acid levels in conditions such as tumor lysis syndrome and gout.
Gout suppressants are medications, such as colchicine and various non-steroidal anti-inflammatory drugs (NSAIDs), that are used to reduce inflammation and pain caused by acute gout attacks, but they do not lower uric acid levels in the blood.
Gout suppressants are a type of medication used to treat acute gout attacks and reduce the risk of future episodes. They work by decreasing the production of uric acid in the body or improving its elimination, thereby reducing the formation of uric acid crystals that cause inflammation and pain in the joints. Common examples of gout suppressants include:
1. Colchicine: This medication is often used to treat acute gout attacks by reducing inflammation and swelling in the affected joint. It should be taken as soon as possible after the onset of symptoms for best results.
2. Nonsteroidal anti-inflammatory drugs (NSAIDs): These medications, such as ibuprofen, naproxen, and celecoxib, can help alleviate pain and inflammation during an acute gout attack. They are usually more effective when taken at the first sign of an attack.
3. Corticosteroids: In some cases, corticosteroid medications like prednisone may be prescribed to treat severe gout attacks that do not respond to other treatments. These drugs can be administered orally or injected directly into the affected joint.
4. Allopurinol and febuxostat: These medications are called xanthine oxidase inhibitors, which reduce uric acid production in the body. They are typically used for chronic gout management to prevent future attacks and lower the risk of complications such as kidney stones and joint damage.
It is important to note that some gout suppressants may have side effects or interact with other medications, so it is crucial to discuss any concerns with a healthcare provider before starting treatment. Additionally, lifestyle changes such as maintaining a healthy weight, following a low-purine diet, and staying hydrated can help manage gout symptoms and lower the risk of future attacks.
Allopurinol is a medication used to prevent gout attacks and kidney stones, as well as to manage the high uric acid levels associated with certain types of cancer treatment, by inhibiting the enzyme xanthine oxidase that is involved in uric acid production.
Allopurinol is a medication used to treat chronic gout and certain types of kidney stones. It works by reducing the production of uric acid in the body, which is the substance that can cause these conditions when it builds up in high levels. Allopurinol is a xanthine oxidase inhibitor, meaning it blocks an enzyme called xanthine oxidase from converting purines into uric acid. By doing this, allopurinol helps to lower the levels of uric acid in the body and prevent the formation of new kidney stones or gout attacks.
It is important to note that allopurinol can have side effects, including rash, stomach upset, and liver or kidney problems. It may also interact with other medications, so it is essential to inform your healthcare provider of any other drugs you are taking before starting allopurinol. Your healthcare provider will determine the appropriate dosage and monitoring schedule based on your individual needs and medical history.
Hyperuricemia is a medical condition defined as an excessively high level of uric acid in the blood, which can potentially lead to the formation of uric acid crystals in the joints and tissues, causing inflammation and pain, and possibly resulting in gout or kidney stones.
Hyperuricemia is a medical condition characterized by an excessively high level of uric acid in the blood. Uric acid is a waste product that's produced when the body breaks down purines, which are substances found in certain foods and drinks, such as red meat, seafood, and alcoholic beverages. Normally, uric acid is dissolved in the blood and then excreted by the kidneys through urine. However, if there's too much uric acid in the body or if the kidneys can't eliminate it efficiently, it can build up in the blood, leading to hyperuricemia.
Mild cases of hyperuricemia may not cause any symptoms and may not require treatment. However, high levels of uric acid can lead to the formation of uric acid crystals, which can accumulate in the joints and tissues, causing inflammation and pain. This condition is known as gout. Hyperuricemia can also increase the risk of developing kidney stones and kidney disease.
Hyperuricemia can be caused by several factors, including a diet high in purines, genetic factors, kidney disease, certain medications, and conditions that cause rapid cell turnover, such as cancer or psoriasis. Treatment for hyperuricemia typically involves lifestyle changes, such as reducing the intake of purine-rich foods and beverages, maintaining a healthy weight, and staying hydrated. Medications may also be prescribed to lower uric acid levels in the blood and prevent gout attacks.
Chronic Lymphocytic Leukemia (B-cell) is a type of cancer that originates from the B-lymphocytes, characterized by slow progression, accumulation of malignant cells in the bone marrow, blood, and lymphatic system, and typically manifesting as anemia, fatigue, increased risk of infection, and enlarged lymph nodes.
Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from cells that become certain white blood cells (called lymphocytes) in the bone marrow. The cancer (leukemia) cells start in the bone marrow but then go into the blood.
In CLL, the leukemia cells often build up slowly. Many people don't have any symptoms for at least a few years. But over time, the cells can spread to other parts of the body, including the lymph nodes, liver, and spleen.
The "B-cell" part of the name refers to the fact that the cancer starts in a type of white blood cell called a B lymphocyte or B cell. The "chronic" part means that this leukemia usually progresses more slowly than other types of leukemia.
It's important to note that chronic lymphocytic leukemia is different from chronic myelogenous leukemia (CML). Although both are cancers of the white blood cells, they start in different types of white blood cells and progress differently.
Hematologic neoplasms are a group of malignant disorders originating from hematopoietic cells, including both lymphoid and myeloid lineages, which can give rise to various diseases such as leukemias, lymphomas, and multiple myeloma.
Hematologic neoplasms, also known as hematological malignancies, are a group of diseases characterized by the uncontrolled growth and accumulation of abnormal blood cells or bone marrow cells. These disorders can originate from the myeloid or lymphoid cell lines, which give rise to various types of blood cells, including red blood cells, white blood cells, and platelets.
Hematologic neoplasms can be broadly classified into three categories:
1. Leukemias: These are cancers that primarily affect the bone marrow and blood-forming tissues. They result in an overproduction of abnormal white blood cells, which interfere with the normal functioning of the blood and immune system. There are several types of leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).
2. Lymphomas: These are cancers that develop from the lymphatic system, which is a part of the immune system responsible for fighting infections. Lymphomas can affect lymph nodes, spleen, bone marrow, and other organs. The two main types of lymphoma are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
3. Myelomas: These are cancers that arise from the plasma cells, a type of white blood cell responsible for producing antibodies. Multiple myeloma is the most common type of myeloma, characterized by an excessive proliferation of malignant plasma cells in the bone marrow, leading to the production of abnormal amounts of monoclonal immunoglobulins (M proteins) and bone destruction.
Hematologic neoplasms can have various symptoms, such as fatigue, weakness, frequent infections, easy bruising or bleeding, weight loss, swollen lymph nodes, and bone pain. The diagnosis typically involves a combination of medical history, physical examination, laboratory tests, imaging studies, and sometimes bone marrow biopsy. Treatment options depend on the type and stage of the disease and may include chemotherapy, radiation therapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.
Antineoplastic agents are a category of drugs designed to inhibit or prevent the growth and proliferation of cancer cells, typically by interfering with their cell division and replication processes.
Antineoplastic agents are a class of drugs used to treat malignant neoplasms or cancer. These agents work by inhibiting the growth and proliferation of cancer cells, either by killing them or preventing their division and replication. Antineoplastic agents can be classified based on their mechanism of action, such as alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and targeted therapy agents.
Alkylating agents work by adding alkyl groups to DNA, which can cause cross-linking of DNA strands and ultimately lead to cell death. Antimetabolites interfere with the metabolic processes necessary for DNA synthesis and replication, while topoisomerase inhibitors prevent the relaxation of supercoiled DNA during replication. Mitotic inhibitors disrupt the normal functioning of the mitotic spindle, which is essential for cell division. Targeted therapy agents are designed to target specific molecular abnormalities in cancer cells, such as mutated oncogenes or dysregulated signaling pathways.
It's important to note that antineoplastic agents can also affect normal cells and tissues, leading to various side effects such as nausea, vomiting, hair loss, and myelosuppression (suppression of bone marrow function). Therefore, the use of these drugs requires careful monitoring and management of their potential adverse effects.
Nitrogen compounds refer to chemical substances that contain nitrogen in their molecular structure, which can be organic (containing carbon) like amino acids and nucleic acids, or inorganic (not containing carbon) like ammonia and nitrates.
Nitrogen compounds are chemical substances that contain nitrogen, which is a non-metal in group 15 of the periodic table. Nitrogen forms compounds with many other elements due to its ability to form multiple bonds, including covalent bonds with hydrogen, oxygen, carbon, sulfur, and halogens.
Nitrogen can exist in several oxidation states, ranging from -3 to +5, which leads to a wide variety of nitrogen compounds with different properties and uses. Some common examples of nitrogen compounds include:
* Ammonia (NH3), a colorless gas with a pungent odor, used in fertilizers, cleaning products, and refrigeration systems.
* Nitric acid (HNO3), a strong mineral acid used in the production of explosives, dyes, and fertilizers.
* Ammonium nitrate (NH4NO3), a white crystalline solid used as a fertilizer and explosive ingredient.
* Hydrazine (N2H4), a colorless liquid with a strong odor, used as a rocket fuel and reducing agent.
* Nitrous oxide (N2O), a colorless gas used as an anesthetic and laughing gas in dental procedures.
Nitrogen compounds have many important applications in various industries, such as agriculture, pharmaceuticals, chemicals, and energy production. However, some nitrogen compounds can also be harmful or toxic to humans and the environment if not handled properly.
"Encyclopedias, as a medical topic, refer to comprehensive and organized collections of information on various medical disciplines, theories, practices, diseases, treatments, and related health sciences, serving as extensive reference sources for medical professionals, students, researchers, and general public." (29 words)
An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.
Tumor lysis syndrome
... decrease Clinical tumor lysis syndrome: laboratory tumor lysis syndrome plus one or more of the following: increased serum ... Cairo and Bishop defined a classification system for tumor lysis syndrome. Laboratory tumor lysis syndrome: abnormality in two ... are not features of tumor lysis syndrome.[citation needed] Lactic acidosis. Pretreatment spontaneous tumor lysis syndrome. This ... and high tumor bulk tend to be more associated with the development of tumor lysis syndrome. The most common tumors associated ...
Allopurinol
... was also commonly used to treat tumor lysis syndrome in chemotherapeutic treatments, as these regimens can rapidly ... Jeha S (October 2001). "Tumor lysis syndrome". Seminars in Hematology. 38 (4 Suppl 10): 4-8. doi:10.1016/S0037-1963(01)90037-X ... collectively referred to as DRESS syndrome. Allopurinol is one of the drugs commonly known to cause Stevens-Johnson syndrome ... The most serious adverse effect is a hypersensitivity syndrome consisting of fever, skin rash, eosinophilia, hepatitis, and ...
Clofarabine
Under accelerated approval regulations requiring further clinical studies.) Tumor lysis syndrome (TLS). Clofarabine quickly ... Systemic inflammatory response syndrome (SIRS): symptoms include fast breathing, fast heartbeat, low blood pressure, and fluid ... "Antitumor activity of 2-fluoror-2'deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase ...
Uric acid
Tumor lysis syndrome, an emergency condition that may result from blood cancers, produces high uric acid levels in blood when ... Tumor lysis syndrome may lead to acute kidney injury when uric acid crystals are deposited in the kidneys. Treatment includes ... Tumor lysis syndrome, a metabolic complication of certain cancers or chemotherapy, due to nucleobase and potassium release into ... Howard, S. C.; Jones, D. P.; Pui, C.-H. (12 May 2011). "The Tumor Lysis Syndrome". The New England Journal of Medicine. 364 (19 ...
Rasburicase
Wilson FP, Berns JS (October 2012). "Onco-nephrology: tumor lysis syndrome". Clin J Am Soc Nephrol. 7 (10): 1730-9. doi:10.2215 ... Cammalleri L, Malaguarnera M (2007). "Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout ... "Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer". The Cochrane Database of ... for the prevention and treatment of tumor lysis syndrome (TLS) in people receiving chemotherapy for hematologic cancers such as ...
Lactic acidosis
Darmon, Michael; Malak, Sandra; Guichard, Isabelle; Schlemmer, Benoit (July-September 2008). "Acute tumor lysis syndrome: a ... Pheochromocytoma Tumor lysis syndrome D-lactic acidosis due to intestinal bacterial flora production in short gut syndrome ... the systemic inflammatory response syndrome due to another cause, severe physical trauma, or severe depletion of body fluids. ... "A guide to diagnosis and treatment of Leigh syndrome". Journal of Neurology, Neurosurgery & Psychiatry. 85 (3): 257-65. doi: ...
Post-transplant lymphoproliferative disorder
All of these findings together can suggest tumor lysis syndrome.[citation needed] The disease is an uncontrolled proliferation ... Such antibodies include ATG, ALG and OKT3 (muromonab-CD3).[citation needed] Polyclonal PTLD may form tumor masses and present ... Pain or discomfort may result from lymphadenopathy or mass effect from growing tumors. Dysfunction may occur in organs affected ...
Venetoclax
Major side effects include tumor lysis syndrome and severe neutropenia. Additionally, this drug may cause fertility problems in ...
Hypermagnesemia
Less common causes include tumor lysis syndrome, seizures, and prolonged ischemia. Diagnosis is based on a blood level of ...
Acute kidney injury
Other causes of intrinsic AKI are rhabdomyolysis and tumor lysis syndrome. Certain medication classes such as calcineurin ... leading to cardiorenal syndrome), hepatorenal syndrome in the context of liver cirrhosis, and local changes to the blood ...
Thalidomide
As it kills cancer cells, it can cause tumor lysis syndrome. Thalidomide can prevent menstruation. In addition, very common ( ... Severe side effects include tumor lysis syndrome, blood clots, and peripheral neuropathy. Use of thalidomide in pregnancy can ... Thalidomide can cause liver damage and severe skin reactions like Stevens-Johnson syndrome. It tends to make people sleepy, ... March 1998). "Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, ...
Ibrutinib
Kaur V, Mehta P, Johnsurd J, Govindarajan R (November 2014). "Ibrutinib-associated tumor lysis syndrome in a patient with ... tumor lysis syndrome, high uric acid levels, dizziness, blurred vision, atrial fibrillation, subdural hematoma, nosebleeds, ... which drives cells into apoptosis and/or disrupts cell migration and adherence to protective tumour microenvironments. ...
Hyperphosphatemia
Causes include kidney failure, pseudohypoparathyroidism, hypoparathyroidism, diabetic ketoacidosis, tumor lysis syndrome, and ...
Nephrocalcinosis
These include tumor lysis syndrome, acute phosphate nephropathy, and occasional cases of enteric hyperoxaluria. ... Milk-alkali syndrome Hypervitaminosis D Multiple myeloma These conditions can cause nephrocalcinosis in association with ... or in children with Bartter syndrome in whom essential tubular salt reabsorption is compromised. There are several causes of ...
Leukostasis
Such rapid and massive lysis of tissue poses a risk of complications (tumor lysis syndrome), but it is necessary to avoid a ... Patients with hyperleukocytosis associated with leukemia are always considered candidates for tumor lysis syndrome prophylaxis ... Disseminated intravascular coagulation and spontaneous tumor lysis syndrome can develop before and after chemotherapy treatment ... Spontaneous tumor lysis syndrome is present in approximately 10 percent of patients with leukostasis. Lab tests are used to ...
Gandotinib
In a phase I trial, 16% of patients receiving the drug developed tumor lysis syndrome. A phase II trial is underway for ...
Menarini
... in the prevention of tumor lysis syndrome (TLS): Florence study". Clin Oncol. 32. June 2014. Retrieved 2016-11-07. Tack, Jan F ... "Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence ... in comparison to Allopurinol reduces exposure to uric acid in patients at intermediate to high risk of tumor lysis syndrome: ... "Sa1080 Concordance Among Outcome Variables Assessing the Response to Treatment With Ibodutant in Irritable Bowel Syndrome With ...
Bland embolization
It can be thought of as a type of tumor lysis syndrome. After abrupt ischemic tumor cell death, the tumor cells lyse and ... The anti-tumor effects are solely based on tumor ischemia and infarction of tumor tissue, as no chemotherapeutic agents are ... For solitary tumors, an attempt is made to embolize the tumor as selectively as possible. The initial arteriogram is reviewed ... Tumor response rate was the primary endpoint using Response Evaluation Criteria In Solid Tumors (RECIST) criteria, , while time ...
Burkitt lymphoma
This rapid response to chemotherapy can be hazardous to the patient, as a phenomenon called "tumor lysis syndrome" could occur ... The tumor cells are mostly medium in size (i.e., tumor nuclei size similar to that of histiocytes or endothelial cells). "Small ... The tumor suppressors ARF and USP7 are also frequently mutated in Burkitt lymphoma leading to MDM2 inhibition of the tumor ... These additional mutations include mutations of the tumor suppressor TP53, which interacts with the tumor suppressor p53 (which ...
Bortezomib
... tumour lysis syndrome, heart failure, and reversible posterior leukoencephalopathy syndrome. It is in the class of medications ... and cell-culture and xenograft data support a similar function in solid tumor cancers. While multiple mechanisms are likely to ...
Chemotherapy
Nephrotoxicity (kidney damage) can be caused by tumor lysis syndrome and also due direct effects of drug clearance by the ... Adeyinka, Adebayo; Bashir, Khalid (2022), "Tumor Lysis Syndrome", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID ... Blood vessels in tumors are very different from those seen in normal tissues. As a tumor grows, tumor cells furthest away from ... some people develop tumor lysis syndrome. The rapid breakdown of cancer cells causes the release of chemicals from the inside ...
Hyperuricemia
... tumor lysis syndrome produces extreme levels of uric acid, mainly leading to kidney failure. The Lesch-Nyhan syndrome is also ... Metabolic syndrome often presents with hyperuricemia. Prognosis is good with regular consumption of allopurinol or febuxostat.[ ... 2006). "A causal role for uric acid in fructose-induced metabolic syndrome". Am. J. Physiol. Renal Physiol. 290 (3): F625-31. ... Miller A, Adeli K (March 2008). "Dietary fructose and the metabolic syndrome". Curr. Opin. Gastroenterol. 24 (2): 204-9. doi: ...
CHOP (chemotherapy)
Allopurinol is typically co-administered prophylactically to prevent hyperuricemia that results from tumor lysis syndrome, the ... "Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas". N Engl J Med. 353 (10): 988-98. doi:10.1056/ ... result of rapid death of tumor cells.[citation needed] A pivotal study published in 1993 compared CHOP to several other ...
Urate oxidase
... often experience tumor lysis syndrome (TLS), which occurs when breakdown of tumor cells by chemotherapy releases uric acid and ... Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A (March 2003). "Incidence of tumor lysis syndrome in children with ...
Lenalidomide
... tumor lysis syndrome, tumor flare reaction, hypothyroidism, and hyperthyroidism. Lenalidomide is related to thalidomide, which ... It is a more potent molecular analog of thalidomide, which inhibits tumor angiogenesis, tumor-secreted cytokines, and tumor ... or intermediate-1-risk myelodysplastic syndromes who have chromosome 5q deletion syndrome (5q- syndrome) with or without ... or intermediate-1-risk myelodysplastic syndromes who have 5q- deletion syndrome but no other cytogenetic abnormalities and are ...
Hypocalcemia
... active vitamin D Hypoparathyroidism/genetic After surgery hypoparathyroidism Hungry bone syndrome Tumour lysis syndrome Acute ... tumor lysis syndrome, and medications such as bisphosphonates or denosumab. Diagnosis should generally be confirmed with a ...
Cytokine release syndrome
... from other adverse effects-for example tumor lysis syndrome requires different interventions. As of 2015, differential ... In immunology, cytokine release syndrome (CRS) is a form of systemic inflammatory response syndrome (SIRS) that can be ... and systemic inflammatory response syndrome (SIRS). Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ... Cytokine reaction syndrome may also be induced by certain medications, such as the CD20 antibody rituximab and the CD19 CAR T ...
Hyperkalemia
Increased tissue breakdown such as rhabdomyolysis, burns, or any cause of rapid tissue necrosis, including tumor lysis syndrome ... Gordon's syndrome (pseudohypoaldosteronism type II) ("familial hypertension with hyperkalemia"), a rare genetic disorder caused ...
Cancer signs and symptoms
Infection Deep Vein Thrombosis Pulmonary Embolism Tumor Lysis Syndrome Muscle Aches Symptoms that require immediate treatment ... Paraneoplastic Syndromes: Some cancers produce "ectopic" hormones, particularly when tumors arise from neuroendocrine cells, ... Many tumors stimulate new blood vessel formation which serves to supply the tumor rather than the normal, healthy tissue. The ... Examples include the production of parathyroid hormones by parathyroid tumors or serotonin by carcinoid tumors. In these cases ...
List of MeSH codes (C20)
Sézary syndrome MeSH C20.683.515.950 - tumor lysis syndrome MeSH C20.683.780.250 - cryoglobulinemia MeSH C20.683.780.490 - ... Guillain-Barré syndrome MeSH C20.111.258.750.400.500 - Miller Fisher syndrome MeSH C20.111.258.750.600 - hereditary sensory and ... Schnitzler syndrome MeSH C20.683.780.650 - multiple myeloma MeSH C20.683.780.750 - POEMS syndrome MeSH C20.683.780.925 - ... stiff-person syndrome MeSH C20.111.258.925 - uveomeningoencephalitic syndrome MeSH C20.111.258.962 - vasculitis, central ...
Tumor lysis syndrome - Wikipedia
... decrease Clinical tumor lysis syndrome: laboratory tumor lysis syndrome plus one or more of the following: increased serum ... Cairo and Bishop defined a classification system for tumor lysis syndrome. Laboratory tumor lysis syndrome: abnormality in two ... are not features of tumor lysis syndrome.[citation needed] Lactic acidosis. Pretreatment spontaneous tumor lysis syndrome. This ... and high tumor bulk tend to be more associated with the development of tumor lysis syndrome. The most common tumors associated ...
Tumor lysis syndrome: Symptoms, causes, treatment, and more
Tumor lysis syndrome is a rare but serious complication that can occur during cancer treatment. Learn more. ... syndrome.8.aspx. *. Matuszkiewicz-Rowinska, J., et al. (2020). Prevention and treatment of tumor lysis syndrome in the era of ... Tumor lysis syndrome (TLS) is a rare but potentially fatal complication that can occur during cancer treatment. Doctors can ... www.dovepress.com/prevention-and-treatment-of-tumor-lysis-syndrome-and-the-efficacy-and--peer-reviewed-fulltext-article-OTT. ...
Tumor Lysis Syndrome: Practice Essentials, Pathophysiology, Etiology
It usually occurs in patients with bulky, rapidly proliferating, treatment-responsive tumors. ... Tumor lysis syndrome refers to the constellation of metabolic disturbances that may follow the initiation of cancer treatment. ... encoded search term (Tumor Lysis Syndrome) and Tumor Lysis Syndrome What to Read Next on Medscape ... silent laboratory evidence of tumor lysis syndrome occurred in 70% of cases, but clinically significant tumor lysis syndrome ...
Tumor lysis syndrome
... (TLS) is an oncologic emergency due to the rapid lysis of tumor cells and subsequent release of large ... Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive ... The tumor lysis syndrome. N Engl J Med 2011;364:1844-54. ... Pathophysiology of tumor lysis syndrome and pathway of purine ... 종양용해증후군은 대사이상만 나타나는 검사상 종양용해증후군(laboratory tumor lysis syndrome, LTLS)과, 여기에 임상증상을 동반한 임상적 종양용해증후군(clinical TLS, CTLS)으로 분류된다. ...
tumor lysis syndrome symptoms - Microporator
... tumor lysis, tumor lysis labs, tumor lysis syndrome, tumor lysis syndrome labs, tumor lysis syndrome symptoms, tumor markers, ... tumor on pituitary gland, tumor or tumour, tumor suppressor genes, tumor symptoms, tumor treating fields, tumor with teeth, ... tumor lysis syndrome symptoms DRG Neurons Promote Perineural Invasion of Endometrial Cancer via GluR2. Experimental Study of ... tumor microenvironment, tumor mutation burden, tumor mutational burden, tumor of striated muscle tissue, ...
Tumor Lysis Syndrome: Practice Essentials, Pathophysiology, Etiology
It usually occurs in patients with bulky, rapidly proliferating, treatment-responsive tumors. ... Tumor lysis syndrome refers to the constellation of metabolic disturbances that may follow the initiation of cancer treatment. ... encoded search term (Tumor Lysis Syndrome) and Tumor Lysis Syndrome What to Read Next on Medscape ... Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med. 1997 Nov. 103(5):363-7. [QxMD MEDLINE Link]. ...
![Carfilzomib (Kyprolis) [Medicare] - Medical Clinical Policy Bulletins | Aetna](data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABAAAAAQCAMAAAAoLQ9TAAAAWlBMVEX///+EL6eMPa2INqqDLqaDLaZ2GJ13Gp58IaGAKaTw5vT69/vAldJ5HZ9zEpvs3/G7jM7cxObStN+PQa/k0etrBpX59PrizuqnasDm1u23hsuZUrbt4vOtdcRVa9oSAAAAjUlEQVQYlV2P2xLDIAgFMVFAjTFpc2/7/79ZUDvTyT7hDnAQuhvgBE4oJK81GGP9NIcYw6NjY4wKgsbTF2EQluE6RcypCtcT8xoBNqzCciLHu7Rg23HkuiNWwYM+AvxGSsg5rtIVSIXzIi4cReQiLOr08ZKZN/3tUDZqKR9N2fKy62FWYNLPUUpSQ3/jC9lHBYdVy+a/AAAAAElFTkSuQmCC)
Carfilzomib (Kyprolis) [Medicare] - Medical Clinical Policy Bulletins | Aetna
Tumor Lysis Syndrome. Tumor lysis syndrome (TLS) occurred following Kyprolis (carfilzomib) administration in ,1% of patients. ... Thus, a basic strategy of tumor targeting therapy should include not only killing regular cancer cells but also blocking tumor ... Posterior Reversible Encephalopathy Syndrome (PRES). PRES, formerly termed Reversible Posterior Leukoencephalopathy Syndrome ( ... In SHP77 flank xenograft tumors, CFZ monotherapy inhibited tumor growth and prolonged survival, while no additive or ...
Vivimusta (Bendamustine Hydrochloride Injection): Uses, Dosage, Side Effects, Interactions, Warning
Tumor Lysis Syndrome. Tumor lysis syndrome associated with bendamustine hydrochloride has occurred in patients in clinical ... Serious adverse reactions reported in clinical trials included myelosuppression, infection, pneumonia, tumor lysis syndrome and ... Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with ... The median age was 60 years, 65% were male, and 95% had a baseline WHO performance status of 0 or 1. Major tumor subtypes were ...
Tumor Lysis Syndrome (TLS) « Cancer and Beyond
Tumour Lysis Syndrome in Solid Tumours Associated with Tyrosine Kinase Inhibitors - A Case Illustrated Review | touchONCOLOGY
... tumor lysis syndrome, Clin J Am Soc Nephrol, 2012;7:1730-9. 8. Gemici C, Tumour lysis syndrome in solid tumours, Clin Oncol, ... Tumor lysis syndrome in solid tumors: an up to date review of the literature, Rare Tumors, 2014;6:5389. 6. Howard SC, Trifilio ... Saylor PJ, Reid TR, Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase ... hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome, ...
Ruxience Injection: Package Insert - Drugs.com
Tumor Lysis Syndrome (TLS) Advise patients to contact their healthcare provider immediately for signs and symptoms of tumor ... 5.5 Tumor Lysis Syndrome (TLS). Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor ... Tumor Lysis Syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause you to have: *kidney failure and ... Tumor lysis syndrome: Administer aggressive intravenous hydration, anti-hyperuricemic agents, monitor renal function (5.5). ...
Morning Report Perspectives & Tumor Lysis Syndrome - WCH Medicine Blog
Morning Report Perspectives & Tumor Lysis Syndrome 1) For those who feel a sense of anxiety and trepidation during Morning ... The Tumor Lysis Syndrome. N Engl J Med 2011; 364:1844-1854. FULL ARTICLE ... is the tumor lysis syndrome. Release of intracellular contents from rapidly proliferating abnormal white blood cells results in ...
DailyMed - RETEVMO- selpercatinib capsule
5.7 Tumor Lysis Syndrome Tumor lysis syndrome (TLS) occurred in 0.6% of patients with medullary thyroid carcinoma receiving ... 5.7 Tumor Lysis Syndrome 5.8 Risk of Impaired Wound Healing 5.9 Hypothyroidism 5.10 Embryo-Fetal Toxicity 6 ADVERSE REACTIONS ... Tumor lysis syndrome (TLS). TLS is caused by a fast breakdown of cancer cells. TLS can cause kidney failure, the need for ... Tumor Lysis Syndrome Advise patients to contact their healthcare provider promptly to report any signs and symptoms of TLS [see ...
Buy Cytoxan Shipped Ups, Cytoxan and tumor lysis syndrome
Fatal Tumor Lysis Syndrome Following Sorafenib Treatment | Habib | Journal of Medical Cases
However tumor lysis syndrome was reported in 2 cases only following sorafenib treatment. Here we report a fatal case of tumor ... Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol. 2009;15(35):4464 ... Shiozawa K, Watanabe M, Takenaka H, Nagai H, Ishii K, Sakai K, Sumino Y. Tumor lysis syndrome after sorafenib for ... Severe adverse effects are rare and tumor lysis syndrome (TLS) was reported in two cases only [3, 4]. In one of the cases it ...
American Society of Nephrology | Kidney Week - Abstract Details (2023)
Spontaneous Tumor Lysis Syndrome. Session Information. *Onconephrology: Immunological Cross-Talk. November 04, 2023 , Location ... Tumor lysis syndrome is a life-threatening oncological emergency characterized by metabolic abnormalities including ... Spontaneous Tumor Lysis Syndrome. November 04, 2023 , 10:00 AM - 12:00 PM ...
Lymphoblastic Lymphoma: Practice Essentials, Etiology and Pathophysiology, Epidemiology
Tumor lysis syndrome is a phenomenon observed most commonly in lymphomas with bulky masses. Tumor lysis occurs when cytotoxic ... Continue chemotherapy, because the lysing of tumor cells resolves as the tumor burden decreases. If tumor lysis is anticipated ... Treatment for tumor lysis syndrome is immediate intensive care with cardiac monitoring. Dialysis may be necessary. ... What is tumor lysis syndrome and how is it treated in patients with lymphoblastic lymphoma? ...
ARIAD Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy and Safety Data from...
Tumor Lysis Syndrome: Two patients (,1%, one with AP-CML and one with BP-CML) treated with Iclusig developed serious tumor ... lysis syndrome. Hyperuricemia occurred in 7% (31/449) of patients. Due to the potential for tumor lysis syndrome in patients ... cases of reversible posterior leukoencephalopathy syndrome (RPLS-also known as Posterior Reversible Encephalopathy Syndrome ( ...
Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual...
Tumor lysis syndrome: Patients with rapidly proliferating tumor and high tumor burden may be at increased risk. Monitor closely ... Serious dermatologic reactions: Fatal and serious cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) ... and acute respiratory distress syndrome, have been reported. Monitor patients for signs and symptoms, including cough and ... Extended Follow-Up with Evaluation of Baseline Metabolic Tumor Volume and PET2 ...
"Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Manag" by Lindsey E. Roeker, Neil Bailey et al.
Clinical trials using the approved dose escalation schedule report negligible rates of clinical tumor lysis syndrome (TLS). We ... Roeker, Lindsey E.; Bailey, Neil; and See full list of authors in comments, "Adverse Events, Patterns of Tumor Lysis Syndrome ... Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of ... Clinical trials using the approved dose escalation schedule report negligible rates of clinical tumor lysis syndrome (TLS). We ...
Pediatric Acute Lymphoblastic Leukemia: Practice Essentials, Background, Pathophysiology
... to evaluate for leukemic kidney involvement as a risk assessment for tumor lysis syndrome ... Although a few cases are associated with inherited genetic syndromes (eg, Down syndrome) or congenital immunodeficiencies (eg, ... Although a few cases are associated with inherited genetic syndromes (eg, Down syndrome) or congenital immunodeficiencies (eg, ... Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. ...
Poteligeo Side Effects: Common, Severe, Long Term
Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting | BioSpace
Tumor Lysis Syndrome (TLS): Tumor lysis syndrome, including fatal cases, has been reported in patients receiving Gazyva. Gazyva ... Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for ... Tumor lysis syndrome: Caused by the fast breakdown of cancer cells. Signs include nausea, vomiting, diarrhea, and lack of ... Cytokine release syndrome (CRS) was the most common adverse event, occurring in 63.0% of patients. These data were recently ...
CAR T-Cell Therapy in Treating Cancer | CancerCare
Tumor Lysis Syndrome (TLS). When cancer cells break down (are destroyed) very quickly, they release large amounts of potassium ... Cytokine-Release Syndrome (CRS). The infusion of CAR T-cells into the body results in the production of large numbers of ... Monoclonal antibodies are lab-generated proteins that target specific tumor antigens (substances that the immune system sees as ... Bispecific antibodies are lab-generated proteins that target specific tumor antigens (as do monoclonal antibodies) but also ...
Hieu Doan
Endothelial Cells Activated by Tumor Lysis Syndrome and AKI: Beyond Crystal MechanismsHistones Promote Foxp3+ Suppressive Treg...
Subclinical tumor lysis-like syndrome during treatment of visceral leishmaniasis with low-dose intermittent liposomal...
Subclinical tumor lysis-like syndrome during treatment of visceral leishmaniasis with low-dose intermittent liposomal ... 15] Liberopoulos E, Alexandridis G, Elisaf M. A tumor lysis-like syndrome during therapy of visceral leishmaniasis. Ann Clin ... This observation suggests that treatment of VL with intermittent L-AmB causes a subclinical tumor lysis-like syndrome, ... 17] Cairo MS, Bishop M. Tumor lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004, 127, 3-11 http ...
The Veterinary ICU Book - 1st Edition - Wayne Wingfield - Marc Raffe
DailyMed - HYDROXYUREA capsule
Metabolism and Nutrition disorders: anorexia, tumor lysis syndrome. * Skin and subcutaneous tissue disorders: maculopapular ... Individualize treatment based on tumor type, disease state, response to treatment, patient risk factors, and current clinical ... Individualize treatment based on tumor type, disease state, response to treatment, patient risk factors, and current clinical ... thrice weekly for 6 months to female rats increased the incidence of mammary tumors in rats surviving to 18 months compared to ...
Spontaneous tumor lysis syIntracellular contentsPathophysiology2016ProphylaxisRhabdomyolysisHematologic malignanciesMalignanciesClinicalPediatricHigh tumorMedullary thyroiAbnormalitiesSymptomsAntigensLeukemiasSystemicAdministerSorafenibHepatocellular carcinomaClinicallyOncologicHypocalcemiaChemotherapyRenalProliferationOccursFatalRiskHyperkalemiaSolidTreatmentGradePatientsCellsLymphomasCommonAdverseBoneMultipleMechanismsKidneyCell
Spontaneous tumor lysis sy1
- Pretreatment spontaneous tumor lysis syndrome. (wikipedia.org)
Intracellular contents2
- Rapid tumor cell turnover results in release of intracellular contents into the circulation. (medscape.com)
- The pathophysiology of TLS is characterised by an extensive breakdown of tumour cells releasing intracellular contents into the bloodstream, leading to acidosis, hyperuricemia, hyperphosphatemia, and hyperkalemia. (touchoncology.com)
Pathophysiology1
- Pathophysiology of tumor lysis syndrome and pathway of purine catabolism. (pemj.org)
20162
- Although several subtypes of T-cell lymphoblastic leukemia/lymphoma exist, early T-cell precursor lymphoblastic leukemia (ETP-ALL) is the only subtype recognized as an entity in the revised 2016 WHO tumor classification. (medscape.com)
- 2016. Tumor Lysis Syndrome. (kumc.edu)
Prophylaxis2
- Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. (medscape.com)
- Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Manag" by Lindsey E. Roeker, Neil Bailey et al. (providence.org)
Rhabdomyolysis1
- Hemolysis, Tumor lysis syndrome, or Rhabdomyolysis due to the ongoing release of potassium. (who.int)
Hematologic malignancies3
- Tumor lysis syndrome arises most commonly after the start of initial chemotherapeutic treatment, but spontaneous cases have increasingly been documented in patients with high-grade hematologic malignancies. (medscape.com)
- [ 6 , 7 ] The syndrome has also been reported with other hematologic malignancies and with solid tumors such as hepatoblastoma and stage IV neuroblastoma. (medscape.com)
- More than 30 company-sponsored abstracts have been accepted, supporting the data from clinical development programs investigating innovative treatments for prostate cancer, hematologic malignancies and solid tumors. (jnj.com)
Malignancies2
- Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. (medscape.com)
- There are a variety of tyrosine kinase inhibitors (TKIs) that are used in oncology for the treatment of malignancies now and consequently there have been increased observations of tumour lysis syndrome (TLS) associated with these drugs. (touchoncology.com)
Clinical6
- Patient characteristics: Certain patient-related factors can affect the development of clinical tumor lysis syndrome. (wikipedia.org)
- 종양용해증후군은 대사이상만 나타나는 검사상 종양용해증후군(laboratory tumor lysis syndrome, LTLS)과, 여기에 임상증상을 동반한 임상적 종양용해증후군(clinical TLS, CTLS)으로 분류된다. (pemj.org)
- Mirrakhimov AE, Voore P, Khan M, Ali AM. Tumor lysis syndrome: A clinical review. (medscape.com)
- Mughal TI, Ejaz AA, Foringer JR, Coiffier B. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. (medscape.com)
- Clinical trials using the approved dose escalation schedule report negligible rates of clinical tumor lysis syndrome (TLS). (providence.org)
- Individualize treatment based on tumor type, disease state, response to treatment, patient risk factors, and current clinical practice standards. (nih.gov)
Pediatric3
- Guideline] Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. (medscape.com)
- Cyclophosphamide is a antineoplastic , immunosuppressive agent that is FDA approved for the treatment of malignant diseases , minimal change nephrotic syndrome in pediatric patients. (wikidoc.org)
- Appropriate studies have not been performed on the relationship of age to the effects of selpercatinib to treat non-small cell lung cancer and solid tumors in the pediatric population. (mayoclinic.org)
High tumor2
- Tumor characteristics: Tumors with a high cell turnover rate, rapid growth rate, and high tumor bulk tend to be more associated with the development of tumor lysis syndrome. (wikipedia.org)
- TLS is frequently observed in children with malignancy, which has high tumor burden, rapid cell turnover or high chemosensitivity (particularly, Burkitt's lymphoma and acute lymphoblastic leukemia), following the initiation of cytotoxic therapy. (pemj.org)
Medullary thyroi2
- 1 TKIs are now therapies used routinely in the treatment of many solid tumours such as gastrointestinal stromal tumour (GIST), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), medullary thyroid cancer, breast cancer and non-small-cell lung carcinoma (Table 1) . (touchoncology.com)
- Selpercatinib is also used to treat advanced or metastatic (cancer that has already spread) medullary thyroid cancer (MTC) in patients whose tumors have abnormal RET (RET-mutant) genes. (mayoclinic.org)
Abnormalities3
- Tumor lysis syndrome (TLS) is a group of metabolic abnormalities that can occur as a complication from the treatment of cancer, where large amounts of tumor cells are killed off (lysed) from the treatment, releasing their contents into the bloodstream. (wikipedia.org)
- The metabolic abnormalities seen in tumor lysis syndrome can ultimately result in serious complications such as acute uric acid nephropathy, acute kidney failure, seizures, cardiac arrhythmias, and death. (wikipedia.org)
- Tumor lysis syndrome is a life-threatening oncological emergency characterized by metabolic abnormalities including hyperuricemia, hyperphosphatasemia, hyperkaliemia and hypocalcemia. (asn-online.org)
Symptoms1
- Cerebral oedema (only with symptoms of intracranial pressure evidenced by computerised tomography) caused by a brain tumour, neuro-surgical intervention, cerebral abscess. (medicines.org.uk)
Antigens2
- Monoclonal antibodies are lab-generated proteins that target specific tumor antigens (substances that the immune system sees as being foreign or dangerous). (cancercare.org)
- Bispecific antibodies are lab-generated proteins that target specific tumor antigens (as do monoclonal antibodies) but also bind proteins on the surface of T-cells. (cancercare.org)
Leukemias1
- One potential complication of lymphoproliferative disorders (such as aggressive lymphomas and leukemias) is the tumor lysis syndrome. (wchcmr.org)
Systemic1
- Tumor lysis syndrome refers to the constellation of metabolic disturbances that occurs when large numbers of neoplastic cells are killed rapidly, leading to the release of intracellular ions and metabolic byproducts into the systemic circulation. (medscape.com)
Administer1
- Tumor lysis syndrome: Administer aggressive intravenous hydration, anti-hyperuricemic agents, monitor renal function ( 5.5 ). (drugs.com)
Sorafenib2
- However tumor lysis syndrome was reported in 2 cases only following sorafenib treatment. (journalmc.org)
- Here we report a fatal case of tumor lysis syndrome 3 weeks following sorafenib treatment in a patient with advanced hepatitis B virus-related hepatocellular carcinoma. (journalmc.org)
Hepatocellular carcinoma1
- Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma. (medscape.com)
Clinically1
- Clinically significant tumor lysis syndrome can occur spontaneously, but it is most often seen 48-72 hours after initiation of cancer treatment. (medscape.com)
Oncologic2
- Tumor lysis syndrome (TLS) is an oncologic emergency due to the rapid lysis of tumor cells and subsequent release of large amounts of intracellular potassium, phosphate, and uric acid into the bloodstream. (pemj.org)
- Tumor lysis syndrome (TLS) is an oncologic emergency that can lead to severe renal impairment, cardiac arrhythmias, seizures, and death. (asn-online.org)
Hypocalcemia1
- Tumor lysis syndrome is characterized by high blood potassium (hyperkalemia), high blood phosphate (hyperphosphatemia), low blood calcium (hypocalcemia), high blood uric acid (hyperuricemia), and higher than normal levels of blood urea nitrogen (BUN). (wikipedia.org)
Chemotherapy6
- citation needed] The important distinction between this syndrome and the post-chemotherapy syndrome is that spontaneous TLS is not associated with hyperphosphatemia. (wikipedia.org)
- citation needed] In post-chemotherapy TLS, tumor cells are destroyed and no new tumor cells are being synthesized. (wikipedia.org)
- Risk factors for tumor lysis syndrome depend on several different characteristics of the patient, the type of cancer, and the type of chemotherapy used. (wikipedia.org)
- As opposed to cytotoxic chemotherapy, TKIs target specific mutated kinases that promote tumour angiogenesis and neoplastic cells growth, proliferation, and resistance to apoptosis. (touchoncology.com)
- Chemotherapy is a cancer treatment approach in which medications are used to inhibit cell proliferation and tumor multiplication, thus avoiding invasion and metastasis and thus eradicate cancer. (bvsalud.org)
- One of the common complications associated with cancer chemotherapy is rapid lysis of expanding tumor cells, known as tumor lysis syndrome (TLS). (bvsalud.org)
Renal1
- Because tumor lysis syndrome is potentially lethal, the main principles of management are (1) identification of high-risk patients with initiation of preventive therapy and (2) early recognition of metabolic and renal complications and the prompt administration of supportive care, including hemodialysis. (medscape.com)
Proliferation1
- In TLS, the breakdown occurs after cytotoxic therapy or from cancers with high cell turnover and tumor proliferation rates. (wikipedia.org)
Occurs1
- Tumor lysis syndrome occurs most often in patients with acute leukemia with high white blood cell (WBC) counts and in those with high-grade lymphomas in response to aggressive treatment. (medscape.com)
Fatal1
- Tumor lysis syndrome (TLS) is a rare but potentially fatal complication that can occur during cancer treatment. (medicalnewstoday.com)
Risk1
- OBJECTIVE: To investigate the risk factors of tumor lysis syndrome (TLS) in relapsed/refractory multiple myeloma (MM) patients undergoing B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. (bvsalud.org)
Hyperkalemia1
- Hyperkalemia and hyperphosphatemia result directly from rapid cell lysis. (medscape.com)
Solid4
- Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. (medscape.com)
- Given the high rate of mortality and the morbidity inherent to TLS, clinicians should be aware that in solid tumour, TKIs may be associated with a delayed onset of TLS. (touchoncology.com)
- The drug exhibits antiproliferative and proapoptotic activities in solid and hematologic tumor cells. (ascopost.com)
- It inhibits proteasome activity in blood and tissue and delays tumor growth in animal models of multiple myeloma, hematologic, and solid tumors. (ascopost.com)
Treatment5
- Cancer treatment aims to destroy a person's tumors . (medicalnewstoday.com)
- When the treatment damages and breaks down cancer cells, the cells release a number of chemicals into a person's bloodstream through a process health experts call lysis. (medicalnewstoday.com)
- Along with imaging studies and biopsy-cytology,tumor markers are playiing an improtant role in cancer diagnosis and treatment. (proprofs.com)
- A treatment effect favoring carfilzomib was observed across all subgroups, but the magnitude of benefit was reduced in patients with higher tumor burden (improvement of 11 months for stage I, 8 months for stage II, and 2 months for stage III). (ascopost.com)
- It is used in patients whose tumors have gotten worse on or after receiving other treatments or there are no treatment options that work well. (mayoclinic.org)
Grade5
- Apart from the tumor lysis syndrome, the only other grade 3/4 toxic effect related to chimeric antigen receptor T cells was lymphopenia. (nih.gov)
- All 18 patients had cytokine release syndrome (CRS), of which 13 (72.2%) developed grade 3-4 CRS. (bvsalud.org)
- Three of 18 patients (16.7%) developed immune effector cell-associated neurotoxicity syndrome (ICANS): two patients with grade 1 ICANS and one with grade 2 ICANS. (bvsalud.org)
- All TLS patients developed cytokine release syndrome (CRS) with an onset of 1.0 (1.0, 6.5) d after CAR-T cell therapy, and 13 cases developed grade 3-4 CRS. (bvsalud.org)
- In our practice, hematologic neoplasms are mainly lymphoproliferative syndromes and the most common varieties are non-Burkitt non Hodgkin lymphoma, high grade lymphomas, chronic lymphocytic lymphoma and multiple myeloma. (bvsalud.org)
Patients3
- Selpercatinib is used to treat locally advanced or metastatic (cancer that has already spread) non-small cell lung cancer (NSCLC) in patients whose tumors have RET fusion-positive genes. (mayoclinic.org)
- Une étude a été menée dans des unités de soins intensifs en chirurgie pour adultes de l'hôpital universitaire de Zagazig, (Égypte) auprès de 25 patients atteints de septicémie, de 27 patients atteints d'une septicémie sévère et de 28 témoins. (who.int)
- Le protocole utilisé dans le traitement du myélome multiple a été le VMCD-REV à 76,92% avec pour réponse thérapeutique complète chez 6 patients, 3 réponses partielles et 4 en cours de traitement. (bvsalud.org)
Cells4
- High turnover of tumor cells leads to spill of potassium into the blood. (wikipedia.org)
- citation needed] One suggestion for the reason of this is that the high cell turnover rate leads to high uric acid levels through nucleobase turnover but the tumor reuses the released phosphate for growth of new tumor cells. (wikipedia.org)
- In some cases, such as the c-Kit mutation observed in GIST, tumour cells can be highly "addicted" to one or more oncogenic kinases 2-4 and the inhibition of these kinases with a TKI can lead to a striking tumour response and trigger tumour lysis syndrome (TLS). (touchoncology.com)
- A low dose (approximately 1.5×10(5) cells per kilogram of body weight) of autologous chimeric antigen receptor-modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia (CLL) expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission. (nih.gov)
Lymphomas1
- The most common tumors associated with this syndrome are poorly differentiated lymphomas (such as Burkitt's lymphoma), other Non-Hodgkin Lymphomas (NHL), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). (wikipedia.org)
Common1
- citation needed] Two common conditions related to excess uric acid, gout and uric acid nephrolithiasis, are not features of tumor lysis syndrome. (wikipedia.org)
Adverse1
- Severe adverse effects are rare and tumor lysis syndrome (TLS) was reported in two cases only [ 3 , 4 ]. (journalmc.org)
Bone1
- Smoldering) multiple myeloma: mismatch between tumor load estimated from bone marrow biopsy at iliac crest and tumor load shown by MRI. (cdc.gov)
Multiple1
- Background aims: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor-T cell (CAR-T) therapy is used for refractory or relapsed multiple myeloma (r/r MM). However, CAR-T-related tumor lysis syndrome (TLS) has been observed. (bvsalud.org)
Mechanisms1
- Our review aims to uncover new mechanisms underlying the metabolic consequences of tumor lysis on AMPK in tumor microenvironment. (bvsalud.org)
Kidney1
- Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. (medscape.com)
Cell1
- Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. (medscape.com)